THE-NAGA-GROUP-AG
1.4.2021 13:16:04 CEST | Business Wire | Press release
The NAGA Group AG (XETRA: N4G, ISIN: DE000A161NR7), provider of the social network for financial market trading NAGA.com, reports its preliminary unaudited results of the first quarter 2021.
Unaudited group sales jumped by 69% to USD 13.7 million (Q1 2020: USD 8.1 million), whilst the number of real-money transactions jumped by 141% to 2.9 million (Q1 2020: 1.2 million). Traded volume crossed USD 70 billion, an increase of 155% (Q1 2020: USD 27 billion). Signups jumped by 480% to 93,000 in Q1 2021 compared to 16,000 account signups in Q1 2020 which resulted in another important milestone for NAGA crossing 1 million registered accounts to date. Another highlight is the growth in transactions of NAGAs unique auto-copy tool. More than 1.4 million trades were copied trades on the NAGA platform, which is an increase of more than 475% compared to 0.27 million copied trades in Q1 2020.
"We are pleased with our Q1 results and especially with the growth metrics. We see three-digit growth across our core metrics. Since the restructuring in 2019 we have delivered growth for the 9th consecutive quarter with Q1 2021 being the strongest in our entire company history. It confirms that 2020 was just the beginning of our growth story. Our social trading business is growing very strongly, and we are clearly expanding our competitive advantage underlining our FinTech and user-experience focused character. Compared to classical brokerage funnels our NAGA-Autocopy drives 150% more in user activity and dramatically improved our conversion rates, reduced acquisition cost metrics and improved churn metrics", comments NAGA CEO Benjamin Bilski.
According to various research outlets, the amount of people joining the stock markets is gaining momentum and will continue to grow strongly. Given NAGAs median client age of 34 and 80% of the transactions taking place on a mobile device, it is a clear confirmation that users appreciate mobile, easy-to-use and community-driven investing platforms that allow them to manage their money independently and invest across all asset classes including digital assets such as Bitcoin. For further diversification, the company plans to open a new local office in Vietnam and actively prepares the entry into the Australian market.
"We are on track to hit our annual targets. We will continue to scale marketing and further optimize our acquisition funnels. Comparing growth and further potential to our competition, but also private FinTech companies, we are very confident about our future upside. Given the shift of user demands and the positive feedback we are receiving about our unique platform, we will announce major exciting product updates in the upcoming quarters to strengthen our position as social neo-broker and investing platform", adds Bilski.
NAGA is also pleased to announce that it has filed an application with OTC Markets Group for the Company's shares to be cross traded publicly on the OTCQX Venture Market which would make NAGA shares more widely available to North American investors. Trading on the US OTCQX market would have no impact on existing NAGA's ordinary shares and no new ordinary shares will be issued as part of the cross-trade. NAGA will continue to rely on the announcements and disclosures it makes to Scale and will have no SEC reporting requirements. Should the application be successful, the cross-trading facility will be provided through OTC Markets Group Inc., located in New York, USA. OTC Markets operates the world's largest electronic interdealer quotation system for US broker dealers and offers multiple media channels to increase the visibility of OTC-traded companies.
"We would like to make NAGA Group AG available to US markets in order to gain access to a broader investor base and enhance our visibility in North America. Cross trading on OTC Markets represents an important development for the company", adds Bilski.
Furthermore, NAGA reports that the convertible bonds with a nominal value of EUR 8 million, as announced in the ad hoc announcement of March 8, 2021, have been placed in full.
###
About NAGA
NAGA is an innovative fintech company that seamlessly connects personal finance transactions and investments through its social trading platform. The company's proprietary platform offers a range of products from stock trading, investments and cryptocurrencies to a physical Mastercard. Additionally, the platform allows for exchanges with other traders, provides relevant information in the feed, and autocopy features for successful members' trades. NAGA is a synergistic total solution that is easily accessible and inclusive. It provides an improved foundation to trade, invest, network, earn and pay. This applies to both fiat and crypto products.
| Language: | English |
| Company: | The NAGA Group AG |
| Hohe Bleichen 12 | |
| 20354 Hamburg | |
| Germany | |
| Email: | info@naga.com |
| Internet | www.naga.com |
| ISIN: | DE000A161NR7 |
| WKN: | A161NR |
| Indices: | Scale 30 |
| Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Scale), Hamburg, Munich, |
| Stuttgart, Tradegate Exchange |
View source version on businesswire.com: https://www.businesswire.com/news/home/20210401005406/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse
Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release
Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
